I am (Bahram Resul, graduated from the college of pharmacy at Baghdad University in 1968. I Attended a PhD program in Medicinal Chemistry at the faculty of Pharmacy, Uppsala University in Sweden. I was working as assistant lecturer in organic chemistry and medicinal chemistry at the faculty of pharmacy, Uppsala university during my Ph.D. program. I Received a Ph.D. in Medicinal Chemistry, in 1982. I was employed at Pharmacia (Now Pfizer) from 1983-1998. I had various positions at Pharmacia during my employment, including head of medicinal chemistry. I am an Associate professor in the department of Neuroscience, Unit of Pharmacology at Uppsala University in Uppsala, Sweden, where I have been employed since leaving Pharmacia. Professor Stjernschantz and I am the inventor of latanoprost (Xalatan) US patent number 5,578, 618. Xalatan is a new drug for the treatment of Glaucoma. Xalatan was approved by the US FDA in 1996. I am also co-authored numerous published papers in the area of medicinal chemistry, pharmacology and ophthalmology (41 papers se attachment 1). I have been the editor of three International Ophthalmology books. I have been an invited speaker at numerous international scientific meetings and presented more than 30 numerous papers related to use of prostaglandins to treat ocular diseases.

I was teaching Organic Chemistry, Stereochemistry and medicinal chemistry at the Faculty of Pharmacy, Uppsala University, Sweden 1977-1982.

I was teaching Pharmacology (peripheral nervous system and Inflammation) at the Faculty of Medicine, Uppsala University, Sweden 1998-2006.

I am also a named inventor on several patents, including multiple patents directed to the use of prostaglandins (se the attachment 2 ). I have received research grants, including grants related to ocular treatments. I have co authored numerous published peer-reviewed papers in the area of prostaglandin research.

I am the founder of the Pharmaceutical manufacturing company Awamedica and was CEO of Awamedica 2006-2018

 

I am currently a dean of the faculty of medicine at the University of Kurdistan Hawler

   
   

1970-1974 Sulaimany University

 

1976-1983 Laboratory assistant, Faculty of Pharmacy, Uppsala, Sweden

 

1983 -1987 Medicinal Chemist, Pharmacia, Uppsala

 

1987-1998 Head of Medicinal Chemistry, prostaglandin Research, Pharmacia, Uppsala, Sweden

 

1998-2006 Associate Professor, Department of Neuroscience,

Unit of Pharmacology. Faculty of Medicine, Uppsala University, Uppsala, Sweden

 

Director of Pharmaceutical and Chemical

Developments at Synphora Ltd (Drug Development Company)

 

2006-2018 CEO

Awamedica Ltd

Drug Manufacturing Company

Kurdistan Region-Iraq

Erbil

 

Current position

Dean

Faculty of Medicine

University of Kurdistan Hawler (UKH)

 

I am the founder of the Pharmaceutical manufacturing company Awamedica and was CEO of Awamedica 2006-2018.

I am the inventor of latanoprost (Xalatan) US patent number 5,578, 618. Xalatan is a new drug for the treatment of Glaucoma. Xalatan was approved by the US FDA in 1996.


1.                  Björn M. Nilsson, Kiyo No, Johan Stjenschantz and Bahram Resul. Synthesis and Structural Activity Relationships of Novile Omega-Chain Modified Prostaglandin F2-alpha Analogues as Antiglaucoma Agents. Manuscript (2002).

2.                  Margareta Björkman, Hisashi Doi, Bahram Resul, Masaki Suzuki, Ryoji Noyori (Nobel Prize), Yasuyoshi Watanabe and Bengt Långström. Synthesis of a 11C-Labelled Prostaglandin F2-alpha Analogue Using an Improved Method For Still Reactions with [11C]Methyl Iodide. J.Labeled Cpd. Radiopharm. 43, 1327-1334 (2000).

3.                  Johan Stjernschantz, Göran Selen, Maria Astin and Bahram Resul. Microvascular Effects of Selective Prostaglandin Analogues in the Eye with Special Reference to Latanoprost and glaucoma Treatment. Progress in Retinal and Eye Research 19, 459-496 (2000)

4.                  Albert Alm et al Uveoscleral Outflow, Biology and Clinical Aspects.

Book published by Mosby-Wolf Medical Communications , Mosby Inernational, 1998  Lynton House, 7-12 Tavistock Square London WCIH 9LD, UK

5.                  Johan Stjernschantz, Göran Selen, Maria Astin, maritha Carlsson and Bahram Resul. Effect of latanoprost on Regional Blood Flow and capillary Permeability in the Monkey eye. Arch. Ophthalmology 117, 1363-1367 (1999)

6.                  Johan Stjernschantz, Göran Selen, Anette Ocklind and Bahram Resul Effects of Latanoprost and Related Prostaglandin Analogues. In Uveoscleral Outflow. Biology and Clinical Aspects (eds. A. Alm and R. N. Weinreb) pp 57-72 mosby-wolfe, London (1998)

7.                  Göran Selen, Johan Stjernschantz and Bahram Resul. Prostaglandin Induced Iridial Pigmentation in Primates. Survey Ophthalmology 117, 1363-1367 (1997).

8.                  Bahram Resul, Johan Stjernschantz, Göran Selen and Laszlo Bito. Structure-Activity Relationships and receptor Profiles of Some Ocular Hypotensive Prostanoids. Survey Ophthalmomlogy 117, 47-52, (1997).

9.                  Charlotta Liljebris, Björn M. Nilsson, Bahram Resul and Uli Hacksell. Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinor-PGF2-alpha isopropyl ester. J. Org. Chem. 61, 4028-4034 (1996)

10.              Charlotta Liljebris, Göran Selen, Bahram Resul, Johan Stjernschantz and Uli Hacksell. Derivatives of 17-Phenyl-18,19,20-Trinorprostaglandin F2-alpha Isopropyl Ester: Potential Antiglaucoma Agents. J. Med. Chem. 38, 289-304 (1995)

11.              Johan Stjernschantz, Göran Selen, Birgitta Sjöquist and Bahram Resul. Preclinical Pharmacology of Latanoprost, a Phenyl Substituted PGF2 alpha Analogue. Adv. Prostaglandin Thromboxane Leukotriene Res. 23, 513-518 (1995)

12.              Samar Basu, Birgitta Sjöquist, Johan Stjernschantz and Bahram Resul. Corneal Permeability to and Ocular Metabolism of Phenyl Substituted Prostaglandin Esters in Vitro. Prostaglandins Leokotrienes and Essential Fatty Acids. 50, 161-168 (1994)

13.              Albert Alm, Jörgen. Villemsin, Per. Tornquist, Agneta Mandahl, Juhani. Airaksinen, Anja. Tuulonen, Anders Marsk, Bahram Resul and Johan Stjernschantz. Intraocular Pressure-Reducing Effect of PhXA41 in Patients with Increased Eye Pressure. A One Month Study. Ophthalmology 100, 1312-1316 (1993)

14.              Bahram Resul and Johan Stjernschantz. Structure Activity Relationships of Prostaglandin Analogues as Ocular Hypotensive Agents. Current Opinion Therapeutic Patents 781-795 (1993)

15.              Stjernschantz J, Resul B, Marsk A, et. alPhenyl substituted prostaglandin esters: effecs in the eye. Invest Ophthalmol Vis Sci. 1991;32 Suppl): 1257.

 

16.              Laszlo Bito, Johan Stjernschantz, Bahram Resul, Olivia Miranda and Samar Basu. The Ocular effects of prostaglandins and the Therapeutic Potential of a New PGF2-alpha Analogue PhXA41 (Latanoprost) for glaucoma management. J. Lipid. Mediat. 6, 535-543 (1993)

17.              Bahram Resul, Johan Stjernschantz, Kiyo No, Charlotta Liljebris, Göran Selen, Maria Astin, Maritha Karlsson and laszlo Bito. Phenyl Substituted Prostaglandins Potent and Selective Antiglaucoma Agents. J. Med. Chem. 36, 243-248 (1993)

18.              Maria Astin, M. Gjötterberg, A. Holst, Göran Selen, Bahram Resul and Johan Stjernschantz: Fluorescein angiographic Study of the Fundus in the Phakik and Aphakik Monkey Eyes Treated With PhXA41. Invest. Ophthalmol. 33, 1078 (1992).’

 

19.              Alm, A., Villumsen,J, Törnquist, P., Mandahl, A., Airaksinen, J., Tuulonen, A., Marsk, A., Resul, B., and Stjernschantz, J., (1993) Intraocular pressure reducing effect of PhXA41 in patients with increased eye pressure. A one month study.  

20.              Charlotta Liljebris, Bahram Resul and Uli Hacksell. Palladium Catalyzed Synthesis of Phenyl Substituted PGF2-alpha Analogues: Potential Antiglaucoma Agents. Bioorganic and Medicinal Chemistry Letters. 3, 241-244 (1992)

21.              Samar Basu, Birgitta Sjöquist, Bahram Resul and Johan Stjernschantz. Presence of a 15-Ketoprostalandin delta 13-reductase in Porcine Cornea. Acta Chem. Scand. 46, 108-110 (1992).

22.              Conny Nordin, Leif Bertilsson, Marja-Liisa dahl, Bahram Resul, Gudrun Toresson and Folke Sjöqvist. Treatment of Depression with E-10-hydroxynorrtryptyline a Pilot Study on Biochemical Effects and Pharmacokinetics. Psychopharmacology 103, 287-290 (1991).

23.              Johan Stjernschantz and Bahram Resul. Phenyl Substituted Prostaglandin Analogues for glaucoma treatment. Drugs of the Future. 17, 691-704 (1992)

24.              Laszlo Bito, carl camras GG. Gum and Bahram Resul. The Ocular Hypotensive effect and side-Effects of Prostaglandins on the Eyes of Experimental Animals. Prog. Clin. Biol. Res. 312, 349-368 (1989)

25.              Laszlo Bito, Olivia C. Miranda, Michael R. Tendler and Bahram Resul. Eicosanoids as a New Class of Ocular Hypotensive Agents. 3. Prostaglandin A2-isopropyl Ester is the Most Potent Reported Hypotensive Agent on Feline Eyes. Exp. Eye Res. 50, 419-428 (1989)

26.              Leif Bertilsson, Conny Nordin, Koichi Otani, Bahram Resul, Mika Scheinin, Bo Siwers and Folke Sjöqvist. Disposition of Single Oral Dose of E-10-Hydroxynortryptyline in Healthy subjects, With Some Observations on Pharmacodynamic Effects. Cli. Pharmacol. Therap. 40, 261-267 (1986)

27.              Sharon Stone-Elander, Martin Ingvar, Peter Johnström, Erling ehrin,Birgit garmelius, Torgny Greitz, J. Lars G. Nilsson, Bahram Resul, Maj-Lis Smith and Lennart Widen. 11C-Labeled 4-isopropylantipyrine: preparation and Biological Evaluation as a Blood Flow Tracer in Positron Emission Tomography (PET). J. Med. Chem. 28, 1325-1328 (1985)

28.              Richard Dahlbom, Björn Ringdahl, Bahram Resul and Donald J. Jenden. Stereoselectivity of Some Muscarinic and Antimuscarinic Agents Related to Oxotremorine. Dynamics of Cholinergic Function Edited by Israel hanin(Plenum Publishing Corporation 1986)

29.              Björn Ringdahl, Bahram Resul, Fredrick J. Ehlert, Donald J. Jenden and Richard Dahlbom. The Conversion of 2-Chloroalkylamine Analogues of Oxotremorine to Azeridinium Ions and their Interactions with Muscarinic Receptors in the Guinea Pig ilium. Molecular Pharmacology 26, 170-179 (1984)

30.              Bahram Resul, Björn Ringdahl, Richard dahlbom and Donald J. Jenden. Muscarinic Activity of Some secondary and Tertiary Amines and Quaternary Ammonium Salts Structurally Related to Oxotremorine. European J. Pharmacol. 87, 387-396 (1983)

31.              Richard dahlbom, Donald J. Jenden, Bahram Resul and Björn Ringdahl. Stereochemical requirements for Central and Peripheral Muscarinic and Antimuscarinic Activity of Some Acetylenic Compounds Relatae to Oxotremorine. Br. J. Pharmacol. 76, 299-304 (1982)

32.              Bahram Resul, Richard Dahlbom, Björn Ringdahl and Donald J. Jenden. N-Alkyl-N-(4-tert-amino-1-methyl-2-butynyl)-carboxamides, a New Class of Potent Oxotremorine Anagonists. Eur., J. Med. Chem.-Chem. Ther. 17, 317-322 (1982)

33.              Björn Ringdahl, Bahram Resul, Donald J. Jenden and Richard Dahlbom. Muscarinic Activity in the Isolated Guinea Pig Ileum of Some carboxamides Related to Oxotremorine. Eur. J. Pharmacol. 85, 79-83 (1982).

34.              Bahram Resul, Tommy Levander, Björn Ringdahl, Tyra Zetterström, and Richard Dahlbom. The Pharmacological Assesment of a New, Potent Oxotremorine Analogue in mice and Rats. Eur. J. Pharmacol. 80, 209-215 (19829

35.              Bahram Resul, Björn Ringdahl and Richard Dahlbom. Acetylene Compounds of Potential Pharmacological value. XXXV. The beta Lactam -analogue of oxotremorine. Eur. J. Med. Chem.-Chimica Therapeutica 16, 379-381 (1981)

36.              Björn Ringdahl, Bahram Resul and J. Cymerman Craig. Circular Dichroism and Conformation of Tertiary Amides. N-acyl pyrrolidines. Chemica Scripta16, 169-172 (1980).

37.              Bahram Resul, Tommy Levander, Tyra Zetterström, Björn Ringdahl, Zuhair Muhi-Eldeen and Richard Dahlbom. Synthesis and Pharmacological Properties of N-[4-(1-Azetidinyl)-2Butynyl]-2-Pyrrolidone, a Highly Potent Oxotremorine Like Agent. Communications, J. Pharm. Pharmacol. 32, 439-440 (1980)

38.              Björn Ringdahl, Bahram Resul and Richard Dahlbom. Stereoselectivity of Some Oxotremorine Antagonists Containig Two Chiral Centers J. Pharm. Pharmacol. 31, 837-839 (1979).

39.              Bahram Resul, Björn Ringdahl and Richard Dahlbom.Acetylene Compounds of Potential Pharmacological Value XXX. Synthesis and Pharmacoplogical Properties of N-(4-tert-amino-2-butynyl)-carboxamide as muscarinic agonists. Acta Pharmaceutica Suecica 16, 161-165 (1979).

40.              Bahram Resul, Björn Ringdahl Uli Hacksell, Uno Svensson and Richard Dahlbom.Acetylene Compounds of Potential Pharmacological Value XXX.I Studies on N-(4-Pyrrolidino-2-pentynyl)-substituted 2-pyrrolidone and Succinimide. Acta Pharmaceutica Suecica 16, 225-232 (1979).

41.              Björn Ringdahl, Bahram Resul, and Richard Dahlbom.Facile Preparation of 3-Acetoxyquinuclidine and 3-quinuclidinol Acta Pharm. Suec. 16, 281-283 (1979)

42.              Björn Ringdahl, Zuhair Muhi-Eldeen, Christine Ljunggren, Bo Karlen, Bahram Resul, and Richard Dahlbom. Acetylene Compounds of Potential Pharmacological Value XXVIII Oxotremorine Analogues Substituted With a Methyl Group in the Lactam Ring. Acta Pharmaceutica Suecica 16, 89-94 (1979).

 

Paper Presentations, oral or poster, in the meetings.

 
  1. Johan Stjernschantz, L. Jonsson, Albert Alm, Christina Linden and Bahram Resul. Genetic variations in the Coding Regions of the FP Prostanoid Receptor in Patients Exhibiting increased Pigmentation of the Iris During Latanoprost Treatment. ARVO (1998)
  2. Bahram Resul and Johan Stjernschantz. The Receptor Profile Prostaglandin-F analogues latanoprost and Isopropyl Unoprostone as Ocular Hypotensive Agents. Int. Glaucoma Symposium (IGS), (1998)
  3. Johan Stjernschantz, Göran Selen, Anette Ocklind and Bahram Resul. Prostaglandin-induced Increase of Iridial Pigmentation. European society of Ophthalmology (SOE) (1997) Hungary
  4. Bahram Resul. Pharmacology of Different Prostaglandins, and Glaucoma Therapy. 2nd Int. Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. Munchen Germany Sept. 11 (1997).
  5. Johan Stjernschantz, Göran Selen, Anette ocklind, Anders Uhlin, Bahram Resul, Björn Svedberg and Krister Rubin. Mechanism of FP-Receptor Mediated Increase in Uveoscleral Outflow. Paper Presented at the International Congress of Eye Research (ICER), Sept. 29 (1996) Japan.
  6. Bahram Resul, Björn Nilsson, Kiyo No, Göran Selen and Johan Stjernschantz. Structural requirements of PGF2-alpha Analogues for Glaucoma Treatment. Paper Presented at the International Congress of Eye Research (ICER), Sept. 29 (1996) Japan
  7. Göran Selen, G. Prota, Johan Stjernschantz, Bahram Resul and Laszlo Bito. Paper Presented at the International Congress of Eye Research (ICER), Sept. 29 (1996) Japan
  8. Bahram Resul, Geza Galambos, Göran Selen and Johan Stjernschantz. Alpha-Chainmodified 17-Phenyl Trinor prostaglandin F2-alpha Analogues as Antiglaucoma Agents. 10Th Int, Conference on prostaglandins and Related Compounds Vienna, Austria Sept. 22 (1996)
  9. Birgitta Sjöquist, Per Byding, Bahram Resul and Johan Stjernschantz. The Systemic Pharmacokinetic of latanoprost in Man after Intravenous and Topical Administration. Paper Presented at the Association for research in Vision and Ophthalmology Meeting (ARVO) May (1994), Sarasota, Florida.
  10. Birgitta Sjöquist, Samar Basu, Bahram Resul and Johan Stjernschantz. The Pharmacokinrtic of Latanoprost in the Cynomologous Monkey. Paper Presented at the Association for research in Vision and Ophthalmology Meeting (ARVO) May (1994), Sarasota, Florida
  11. Maritha Karlsson, Göran Selen, Johan Stjernschantz and Bahram Resul. Receptor Profile of PhXA41 a New Phenyl Substituted Prostaglandin ester. Paper Presented at the 10th International Congress of Eye Research (ICER) Sept. 1992, Stresa, Italy.
  12. Albert Alm, Jörgen Villemsen, Per Törnquist, Agneta Mandahl, Juhani Airaksinen, Anja Tuulonen, Anders Marsk, Bahram Resul and Johan Stjernschantz. The Effect of PhXA41 on Intraocular Hypertension. A Placebo Controlled Double Masked Dose Finding Study. Paper Presented at the 4th Congress and the Glaucoma course of the European Glaucoma Society: May 1992; Amsterdam, the Netherlands.
  13. Göran Selen, Maritha Karlsson, Maria Astin, Johan Stjernschantz and Bahram Resul. Effects of PhXA34 and DH100A Two Phenyl Substituted Prostaglandin esters on Aqueous Humor dynamics and Microcirculations in Monkey Eyes. Paper Presented at the Association for research in Vision and Ophthalmology Meeting (ARVO) May (1991), Sarasota, Florida
  14. Johan Stjernschantz Bahram Resul Anders Marsk, Maria Astin, Maritha Karlsson Göran Selen, , Kiyo No, and.Laszlo Bito. Phenyl Substituted Prostaglandin Esters effects in the eye. Paper Presented at the Association for Research in Vision and Ophthalmology Meeting (ARVO) May (1991), Sarasota, Florida
  15. Hayashi M, Yablonski ME, Bahram Resul and Laszlo Bito. Comparison of the Mechanism of the Ocular Hypotensive Effect of PGF2-alpha isopropyl Ester PGA2 and PGA2-isopropyl ester on Normal and Hypertensive Cat Eyes. Paper Presented at the Association for Research in Vision and Ophthalmology Meeting (ARVO) May (1987), Sarasota, Florida
    

1968 BSc. Pharmacy

College of Pharmacy, Baghdad,  Iraq

 

1982 PhD Medicinal Chemistry, Faculty of Pharmacy, Uppsala, Sweden

 

1995 Associate Professor, Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Sweden

 

I am co-authored numerous published papers in the area of medicinal chemistry, pharmacology and ophthalmology. I have been the editor of three International Ophthalmology books. I have been an invited speaker at numerous international scientific meetings and presented more than 30 numerous papers related to use of prostaglandins to treat ocular diseases.

1. 1997 Williame-Upjohn prize In Recognition of Special Accomplishment

2. 1998 Hungarian Academy of Science for outstanding contribution in Medicinal Chemistry

3. 2004 Swedish Academy of Pharmaceutical Sciences for outstanding contribution in Medicinal Chemistry

1.                  Björn M. Nilsson, Kiyo No, Johan Stjenschantz and Bahram Resul. Synthesis and Structural Activity Relationships of Novile Omega-Chain Modified Prostaglandin F2-alpha Analogues as Antiglaucoma Agents. Manuscript (2002).

2.                  Margareta Björkman, Hisashi Doi, Bahram Resul, Masaki Suzuki, Ryoji Noyori (Nobel Prize), Yasuyoshi Watanabe and Bengt Långström. Synthesis of a 11C-Labelled Prostaglandin F2-alpha Analogue Using an Improved Method For Still Reactions with [11C]Methyl Iodide. J.Labeled Cpd. Radiopharm. 43, 1327-1334 (2000).

3.                  Johan Stjernschantz, Göran Selen, Maria Astin and Bahram Resul. Microvascular Effects of Selective Prostaglandin Analogues in the Eye with Special Reference to Latanoprost and glaucoma Treatment. Progress in Retinal and Eye Research 19, 459-496 (2000)

4.                  Albert Alm et al Uveoscleral Outflow, Biology and Clinical Aspects.

Book published by Mosby-Wolf Medical Communications , Mosby Inernational, 1998  Lynton House, 7-12 Tavistock Square London WCIH 9LD, UK

5.                  Johan Stjernschantz, Göran Selen, Maria Astin, maritha Carlsson and Bahram Resul. Effect of latanoprost on Regional Blood Flow and capillary Permeability in the Monkey eye. Arch. Ophthalmology 117, 1363-1367 (1999)

6.                  Johan Stjernschantz, Göran Selen, Anette Ocklind and Bahram Resul Effects of Latanoprost and Related Prostaglandin Analogues. In Uveoscleral Outflow. Biology and Clinical Aspects (eds. A. Alm and R. N. Weinreb) pp 57-72 mosby-wolfe, London (1998)

7.                  Göran Selen, Johan Stjernschantz and Bahram Resul. Prostaglandin Induced Iridial Pigmentation in Primates. Survey Ophthalmology 117, 1363-1367 (1997).

8.                  Bahram Resul, Johan Stjernschantz, Göran Selen and Laszlo Bito. Structure-Activity Relationships and receptor Profiles of Some Ocular Hypotensive Prostanoids. Survey Ophthalmomlogy 117, 47-52, (1997).

9.                  Charlotta Liljebris, Björn M. Nilsson, Bahram Resul and Uli Hacksell. Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinor-PGF2-alpha isopropyl ester. J. Org. Chem. 61, 4028-4034 (1996)

10.              Charlotta Liljebris, Göran Selen, Bahram Resul, Johan Stjernschantz and Uli Hacksell. Derivatives of 17-Phenyl-18,19,20-Trinorprostaglandin F2-alpha Isopropyl Ester: Potential Antiglaucoma Agents. J. Med. Chem. 38, 289-304 (1995)

11.              Johan Stjernschantz, Göran Selen, Birgitta Sjöquist and Bahram Resul. Preclinical Pharmacology of Latanoprost, a Phenyl Substituted PGF2 alpha Analogue. Adv. Prostaglandin Thromboxane Leukotriene Res. 23, 513-518 (1995)

12.              Samar Basu, Birgitta Sjöquist, Johan Stjernschantz and Bahram Resul. Corneal Permeability to and Ocular Metabolism of Phenyl Substituted Prostaglandin Esters in Vitro. Prostaglandins Leokotrienes and Essential Fatty Acids. 50, 161-168 (1994)

13.              Albert Alm, Jörgen. Villemsin, Per. Tornquist, Agneta Mandahl, Juhani. Airaksinen, Anja. Tuulonen, Anders Marsk, Bahram Resul and Johan Stjernschantz. Intraocular Pressure-Reducing Effect of PhXA41 in Patients with Increased Eye Pressure. A One Month Study. Ophthalmology 100, 1312-1316 (1993)

14.              Bahram Resul and Johan Stjernschantz. Structure Activity Relationships of Prostaglandin Analogues as Ocular Hypotensive Agents. Current Opinion Therapeutic Patents 781-795 (1993)

15.              Stjernschantz J, Resul B, Marsk A, et. alPhenyl substituted prostaglandin esters: effecs in the eye. Invest Ophthalmol Vis Sci. 1991;32 Suppl): 1257.

 

16.              Laszlo Bito, Johan Stjernschantz, Bahram Resul, Olivia Miranda and Samar Basu. The Ocular effects of prostaglandins and the Therapeutic Potential of a New PGF2-alpha Analogue PhXA41 (Latanoprost) for glaucoma management. J. Lipid. Mediat. 6, 535-543 (1993)

17.              Bahram Resul, Johan Stjernschantz, Kiyo No, Charlotta Liljebris, Göran Selen, Maria Astin, Maritha Karlsson and laszlo Bito. Phenyl Substituted Prostaglandins Potent and Selective Antiglaucoma Agents. J. Med. Chem. 36, 243-248 (1993)

18.              Maria Astin, M. Gjötterberg, A. Holst, Göran Selen, Bahram Resul and Johan Stjernschantz: Fluorescein angiographic Study of the Fundus in the Phakik and Aphakik Monkey Eyes Treated With PhXA41. Invest. Ophthalmol. 33, 1078 (1992).’

 

19.              Alm, A., Villumsen,J, Törnquist, P., Mandahl, A., Airaksinen, J., Tuulonen, A., Marsk, A., Resul, B., and Stjernschantz, J., (1993) Intraocular pressure reducing effect of PhXA41 in patients with increased eye pressure. A one month study.  

20.              Charlotta Liljebris, Bahram Resul and Uli Hacksell. Palladium Catalyzed Synthesis of Phenyl Substituted PGF2-alpha Analogues: Potential Antiglaucoma Agents. Bioorganic and Medicinal Chemistry Letters. 3, 241-244 (1992)

21.              Samar Basu, Birgitta Sjöquist, Bahram Resul and Johan Stjernschantz. Presence of a 15-Ketoprostalandin delta 13-reductase in Porcine Cornea. Acta Chem. Scand. 46, 108-110 (1992).

22.              Conny Nordin, Leif Bertilsson, Marja-Liisa dahl, Bahram Resul, Gudrun Toresson and Folke Sjöqvist. Treatment of Depression with E-10-hydroxynorrtryptyline a Pilot Study on Biochemical Effects and Pharmacokinetics. Psychopharmacology 103, 287-290 (1991).

23.              Johan Stjernschantz and Bahram Resul. Phenyl Substituted Prostaglandin Analogues for glaucoma treatment. Drugs of the Future. 17, 691-704 (1992)

24.              Laszlo Bito, carl camras GG. Gum and Bahram Resul. The Ocular Hypotensive effect and side-Effects of Prostaglandins on the Eyes of Experimental Animals. Prog. Clin. Biol. Res. 312, 349-368 (1989)

25.              Laszlo Bito, Olivia C. Miranda, Michael R. Tendler and Bahram Resul. Eicosanoids as a New Class of Ocular Hypotensive Agents. 3. Prostaglandin A2-isopropyl Ester is the Most Potent Reported Hypotensive Agent on Feline Eyes. Exp. Eye Res. 50, 419-428 (1989)

26.              Leif Bertilsson, Conny Nordin, Koichi Otani, Bahram Resul, Mika Scheinin, Bo Siwers and Folke Sjöqvist. Disposition of Single Oral Dose of E-10-Hydroxynortryptyline in Healthy subjects, With Some Observations on Pharmacodynamic Effects. Cli. Pharmacol. Therap. 40, 261-267 (1986)

27.              Sharon Stone-Elander, Martin Ingvar, Peter Johnström, Erling ehrin,Birgit garmelius, Torgny Greitz, J. Lars G. Nilsson, Bahram Resul, Maj-Lis Smith and Lennart Widen. 11C-Labeled 4-isopropylantipyrine: preparation and Biological Evaluation as a Blood Flow Tracer in Positron Emission Tomography (PET). J. Med. Chem. 28, 1325-1328 (1985)

28.              Richard Dahlbom, Björn Ringdahl, Bahram Resul and Donald J. Jenden. Stereoselectivity of Some Muscarinic and Antimuscarinic Agents Related to Oxotremorine. Dynamics of Cholinergic Function Edited by Israel hanin(Plenum Publishing Corporation 1986)

29.              Björn Ringdahl, Bahram Resul, Fredrick J. Ehlert, Donald J. Jenden and Richard Dahlbom. The Conversion of 2-Chloroalkylamine Analogues of Oxotremorine to Azeridinium Ions and their Interactions with Muscarinic Receptors in the Guinea Pig ilium. Molecular Pharmacology 26, 170-179 (1984)

30.              Bahram Resul, Björn Ringdahl, Richard dahlbom and Donald J. Jenden. Muscarinic Activity of Some secondary and Tertiary Amines and Quaternary Ammonium Salts Structurally Related to Oxotremorine. European J. Pharmacol. 87, 387-396 (1983)

31.              Richard dahlbom, Donald J. Jenden, Bahram Resul and Björn Ringdahl. Stereochemical requirements for Central and Peripheral Muscarinic and Antimuscarinic Activity of Some Acetylenic Compounds Relatae to Oxotremorine. Br. J. Pharmacol. 76, 299-304 (1982)

32.              Bahram Resul, Richard Dahlbom, Björn Ringdahl and Donald J. Jenden. N-Alkyl-N-(4-tert-amino-1-methyl-2-butynyl)-carboxamides, a New Class of Potent Oxotremorine Anagonists. Eur., J. Med. Chem.-Chem. Ther. 17, 317-322 (1982)

33.              Björn Ringdahl, Bahram Resul, Donald J. Jenden and Richard Dahlbom. Muscarinic Activity in the Isolated Guinea Pig Ileum of Some carboxamides Related to Oxotremorine. Eur. J. Pharmacol. 85, 79-83 (1982).

34.              Bahram Resul, Tommy Levander, Björn Ringdahl, Tyra Zetterström, and Richard Dahlbom. The Pharmacological Assesment of a New, Potent Oxotremorine Analogue in mice and Rats. Eur. J. Pharmacol. 80, 209-215 (19829

35.              Bahram Resul, Björn Ringdahl and Richard Dahlbom. Acetylene Compounds of Potential Pharmacological value. XXXV. The beta Lactam -analogue of oxotremorine. Eur. J. Med. Chem.-Chimica Therapeutica 16, 379-381 (1981)

36.              Björn Ringdahl, Bahram Resul and J. Cymerman Craig. Circular Dichroism and Conformation of Tertiary Amides. N-acyl pyrrolidines. Chemica Scripta16, 169-172 (1980).

37.              Bahram Resul, Tommy Levander, Tyra Zetterström, Björn Ringdahl, Zuhair Muhi-Eldeen and Richard Dahlbom. Synthesis and Pharmacological Properties of N-[4-(1-Azetidinyl)-2Butynyl]-2-Pyrrolidone, a Highly Potent Oxotremorine Like Agent. Communications, J. Pharm. Pharmacol. 32, 439-440 (1980)

38.              Björn Ringdahl, Bahram Resul and Richard Dahlbom. Stereoselectivity of Some Oxotremorine Antagonists Containig Two Chiral Centers J. Pharm. Pharmacol. 31, 837-839 (1979).

39.              Bahram Resul, Björn Ringdahl and Richard Dahlbom.Acetylene Compounds of Potential Pharmacological Value XXX. Synthesis and Pharmacoplogical Properties of N-(4-tert-amino-2-butynyl)-carboxamide as muscarinic agonists. Acta Pharmaceutica Suecica 16, 161-165 (1979).

40.              Bahram Resul, Björn Ringdahl Uli Hacksell, Uno Svensson and Richard Dahlbom.Acetylene Compounds of Potential Pharmacological Value XXX.I Studies on N-(4-Pyrrolidino-2-pentynyl)-substituted 2-pyrrolidone and Succinimide. Acta Pharmaceutica Suecica 16, 225-232 (1979).

41.              Björn Ringdahl, Bahram Resul, and Richard Dahlbom.Facile Preparation of 3-Acetoxyquinuclidine and 3-quinuclidinol Acta Pharm. Suec. 16, 281-283 (1979)

42.              Björn Ringdahl, Zuhair Muhi-Eldeen, Christine Ljunggren, Bo Karlen, Bahram Resul, and Richard Dahlbom. Acetylene Compounds of Potential Pharmacological Value XXVIII Oxotremorine Analogues Substituted With a Methyl Group in the Lactam Ring. Acta Pharmaceutica Suecica 16, 89-94 (1979).

 
 

Paper Presentations, oral or poster, in the meetings.

 
  1. Johan Stjernschantz, L. Jonsson, Albert Alm, Christina Linden and Bahram Resul. Genetic variations in the Coding Regions of the FP Prostanoid Receptor in Patients Exhibiting increased Pigmentation of the Iris During Latanoprost Treatment. ARVO (1998)
  2. Bahram Resul and Johan Stjernschantz. The Receptor Profile Prostaglandin-F analogues latanoprost and Isopropyl Unoprostone as Ocular Hypotensive Agents. Int. Glaucoma Symposium (IGS), (1998)
  3. Johan Stjernschantz, Göran Selen, Anette Ocklind and Bahram Resul. Prostaglandin-induced Increase of Iridial Pigmentation. European society of Ophthalmology (SOE) (1997) Hungary
  4. Bahram Resul. Pharmacology of Different Prostaglandins, and Glaucoma Therapy. 2nd Int. Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. Munchen Germany Sept. 11 (1997).
  5. Johan Stjernschantz, Göran Selen, Anette ocklind, Anders Uhlin, Bahram Resul, Björn Svedberg and Krister Rubin. Mechanism of FP-Receptor Mediated Increase in Uveoscleral Outflow. Paper Presented at the International Congress of Eye Research (ICER), Sept. 29 (1996) Japan.
  6. Bahram Resul, Björn Nilsson, Kiyo No, Göran Selen and Johan Stjernschantz. Structural requirements of PGF2-alpha Analogues for Glaucoma Treatment. Paper Presented at the International Congress of Eye Research (ICER), Sept. 29 (1996) Japan
  7. Göran Selen, G. Prota, Johan Stjernschantz, Bahram Resul and Laszlo Bito. Paper Presented at the International Congress of Eye Research (ICER), Sept. 29 (1996) Japan
  8. Bahram Resul, Geza Galambos, Göran Selen and Johan Stjernschantz. Alpha-Chainmodified 17-Phenyl Trinor prostaglandin F2-alpha Analogues as Antiglaucoma Agents. 10Th Int, Conference on prostaglandins and Related Compounds Vienna, Austria Sept. 22 (1996)
  9. Birgitta Sjöquist, Per Byding, Bahram Resul and Johan Stjernschantz. The Systemic Pharmacokinetic of latanoprost in Man after Intravenous and Topical Administration. Paper Presented at the Association for research in Vision and Ophthalmology Meeting (ARVO) May (1994), Sarasota, Florida.
  10. Birgitta Sjöquist, Samar Basu, Bahram Resul and Johan Stjernschantz. The Pharmacokinrtic of Latanoprost in the Cynomologous Monkey. Paper Presented at the Association for research in Vision and Ophthalmology Meeting (ARVO) May (1994), Sarasota, Florida
  11. Maritha Karlsson, Göran Selen, Johan Stjernschantz and Bahram Resul. Receptor Profile of PhXA41 a New Phenyl Substituted Prostaglandin ester. Paper Presented at the 10th International Congress of Eye Research (ICER) Sept. 1992, Stresa, Italy.
  12. Albert Alm, Jörgen Villemsen, Per Törnquist, Agneta Mandahl, Juhani Airaksinen, Anja Tuulonen, Anders Marsk, Bahram Resul and Johan Stjernschantz. The Effect of PhXA41 on Intraocular Hypertension. A Placebo Controlled Double Masked Dose Finding Study. Paper Presented at the 4thCongress and the Glaucoma course of the European Glaucoma Society: May 1992; Amsterdam, the Netherlands.
  13. Göran Selen, Maritha Karlsson, Maria Astin, Johan Stjernschantz and Bahram Resul. Effects of PhXA34 and DH100A Two Phenyl Substituted Prostaglandin esters on Aqueous Humor dynamics and Microcirculations in Monkey Eyes. Paper Presented at the Association for research in Vision and Ophthalmology Meeting (ARVO) May (1991), Sarasota, Florida
  14. Johan Stjernschantz Bahram Resul Anders Marsk, Maria Astin, Maritha Karlsson Göran Selen, , Kiyo No, and.Laszlo Bito. Phenyl Substituted Prostaglandin Esters effects in the eye. Paper Presented at the Association for Research in Vision and Ophthalmology Meeting (ARVO) May (1991), Sarasota, Florida
  15. Hayashi M, Yablonski ME, Bahram Resul and Laszlo Bito. Comparison of the Mechanism of the Ocular Hypotensive Effect of PGF2-alpha isopropyl Ester PGA2 and PGA2-isopropyl ester on Normal and Hypertensive Cat Eyes. Paper Presented at the Association for Research in Vision and Ophthalmology Meeting (ARVO) May (1987), Sarasota, Florida
    

I have received research grants, including grants related to ocular treatments. I have co authored numerous published peer-reviewed papers in the area of prostaglandin research. 

This information is private
        Share by: